Theo Roth

Position: MD/PhD Student, UCSF

EmailTheodore.Roth [at] ucsf.edu

My name is Theo Roth, and I'm an MSTP student here at UCSF.  I grew up in St. Louis and Birmingham before getting into research, at the National Institutes of Health. In the lab of Dr. Dorian McGavern I worked out key steps in the immune response to brain injuries using intravital two photon microscopy.  Later at Stanford University I worked with Dr. Matthew Scott developing novel synthetic biology approaches to DNA assembly.  I graduated from Stanford with a BS in Biology and an MS in Biomedical Informatics before starting MD and PhD training at UCSF.  I'm interested in Immunology, Genetics, Informatics, and Genome Editing in the context of Cellular Therapeutics.


Large dataset enables prediction of repair after CRISPR-Cas9 editing in primary T cells.
Leenay RT, Aghazadeh A, Hiatt J, Tse D, Roth TL, Apathy R, Shifrut E, Hultquist JF, Krogan N, Wu Z, Cirolia G, Canaj H, Leonetti MD, Marson A, May AP, Zou J. Nat Biotechnol. 2019 Sep;37(9):1034-1037.

A large CRISPR-induced bystander mutation causes immune dysregulation.
Simeonov DR, Brandt AJ, Chan AY, Cortez JT, Li Z, Woo JM, Lee Y, Carvalho CMB, Indart AC, Roth TL, Zou J, May AP, Lupski JR, Anderson MS, Buaas FW, Rokhsar DS, Marson A. Commun Biol. 2019 Feb 18;2:70.

CRISPR-Cas9 genome engineering of primary CD4+ T cells for the interrogation of HIV-host factor interactions.
Hultquist JF, Hiatt J, Schumann K, McGregor MJ, Roth TL, Haas P, Doudna JA, Marson A Krogan NJ. Nat Protoc. 2019 Jan;14(1):1-27

Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function.
Shifrut E, Carnevale J, Tobin V, Roth TL, Woo JM, Bui CT, Li PJ, Diolaiti ME, Ashworth A, Marson A. Cell 2018 Dec; 175:1-14.

Light-activated cell identification and sorting (LACIS) for selection of edited clones on a nanofluidic device.
Mocciaro A, Roth TL, Bennett HM, Soumillon M, Shah A, Hiatt J, Chapman K, Marson A, Lavieu G. Commun Biol. 2018 May 3;1:41.

Reprogramming human T cell function and specificity with non-viral genome targeting
Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel J, Pellerin L, Carmody D, Alkorta-Aranburu G, del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A. Nature. 2018 Jul;559(7714):405-409.

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms
Farboud B, Jarvis E, Roth TL, Shin J, Corn JE, Marson A, Meyer BJ, Patel NH, Hochstrasser ML. J Vis Exp. 2018 May 25;(135).

Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins
Wu CM, Roth TL, Baglaenko Y, Ferri DM, Brauer P, Zuniga-Pflucker JC, Rosbe KW, Wither JE, Marson A, Allen CDC. J Immunol Methods. 2018 Jun;457:33-40.

Discovery of stimulation-responsive immune enhancers with CRISPR activation
Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, Naddaf N, Chu JS, Ma H, Boyer E, Van Gool F, Huang H, Liu R, Tobin VR, Schumann K, Daly MJ, Farh KK, Ansel KM, Ye CJ, Greenleaf WJ, Anderson MS, Bluestone JA, Chang HY, Corn JE, Marson A. Nature. 549; 111-115 (2017)